Greenwich LifeSciences, Inc. GLSI R2KPHARMA
Company Overview
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +35.40% |
| 6 Months: | -30.92% |
| 3 Months: | -28.31% |
| 1 Month: | +12.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 52.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GLSI Greenwich LifeSciences, Inc. R2KPHARMA | 15.95 | -9.91 | $234.12M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.77M | 4.05M | 4.17M | 7.94M | 5.73M |
| Operating Income | - | - | -336.01K | -244.64K | -210.43K | -256.87K | -600.61K | -753.45K | -866.69K | -1.99M | -773.31K | -2.38M | -2.24M | -1.75M | -2.50M | -2.54M | -2.66M | -2.73M | -2.77M | -4.05M | -4.17M | -7.94M | -5.73M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.77M | -4.05M | -4.17M | -7.94M | -5.73M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.74M | -4.03M | -4.15M | -7.92M | -5.66M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -148.73K | -2.60M | -336.01K | -244.64K | -210.43K | -256.87K | -597.01K | -749.75K | -863.12K | -1.97M | -746.07K | -2.32M | -2.12M | -1.63M | -2.39M | -2.47M | -2.61M | -2.67M | -2.74M | -4.03M | -4.15M | -7.92M | -5.66M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.06 | -0.18 | -0.17 | -0.13 | -0.19 | -0.19 | -0.20 | -0.20 | -0.21 | -0.30 | -0.30 | - | -0.39 |
| R&D Expense | - | - | 284.50K | 149.89K | 150.80K | 158.03K | 281.98K | 556.53K | 657.10K | 1.66M | 633.25K | 1.72M | 1.83M | 1.38M | 2.16M | 2.19M | 2.31M | 2.29M | 2.27M | 3.42M | 3.27M | - | 5.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -3.43M | -1.86M | -4.60M | -8.04M | -9.33M | -17.64M | -19.45M |
| Net Income | -3.43M | -1.86M | -4.57M | -7.83M | -8.89M | -17.41M | -19.36M |
| Diluted EPS | - | - | - | -0.61 | -0.69 | -1.34 | -1.43 |
| R&D Expense | 2.61M | 1.06M | 3.56M | 6.48M | 7.70M | 15.48M | 17.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 26.67K | 28.68M | 27.22M | 13.48M | 6.99M | 4.09M | - | - | - | 6.18M |
| Total Equity | -10.12M | -1.35M | 27.63M | 26.83M | 13.21M | 6.70M | 908.63K | - | - | - | 353.22K |
| Cash & Equivalents | - | 6.83K | 28.66M | 27.20M | 13.47M | 6.99M | 4.09M | - | - | - | 6.18M |
| Total Liabilities | - | 1.38M | 1.05M | 385.17K | 262.90K | 294.41K | 3.19M | 2.55M | 2.52M | 2.02M | 5.82M |
| Current Liabilities | - | 1.38M | 1.05M | 385.17K | 262.90K | 294.41K | 3.19M | - | - | - | 5.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -293.27K | -1.15M | -4.29M | -6.20M | -6.48M | -7.27M | -9.91M |
| Financing Cash Flow | 215.00K | 29.81M | 2.84M | -7.54M | - | 4.37M | 12.00M |
| Share Buybacks | - | - | - | 7.54M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 253.6% | -6.7% | -17.0% | -59.2% | -132.7% | -1,916.5% | -5,480.5% |
| ROCE % | 253.6% | -6.7% | -17.1% | -60.8% | -139.2% | -1,941.1% | -5,505.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 3.31% | 485.85K | $7.61M |
| 2 | Vanguard Capital Management LLC | 1.90% | 278.19K | $4.36M |
| 3 | Geode Capital Management, LLC | 1.15% | 168.18K | $2.64M |
| 4 | State Street Corporation | 0.97% | 143.09K | $2.24M |
| 5 | Vanguard Portfolio Management LLC | 0.55% | 80.86K | $1.27M |
| 6 | Northern Trust Corporation | 0.55% | 80.23K | $1.26M |
| 7 | Bank Of New York Mellon Corporation | 0.33% | 47.90K | $750.59K |
| 8 | Vanguard Fiduciary Trust Co | 0.31% | 45.97K | $720.27K |
| 9 | Morgan Stanley | 0.30% | 43.45K | $680.81K |
| 10 | Goldman Sachs Group Inc | 0.27% | 39.33K | $616.28K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GLSI
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOUVlhaVdScDZXUDUxRS1BazVxWkNyLXBsZlF5R2RpV2dKSVNHd1BibkpYemlJa3VQbW1FNnkwb29VRF9TZTRveURrV3gweTNwdlJuOXV2a2VlZDlTLVFCVWwyUkNsWGhla1JWZk4xLTZIaVY2NElKSVRBZWJYdGhEVy13OGhpVW1YXzBsRm…
What’s Driving GLSI Stock Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOM3RMLUZXOTNFc0pkTk5VN3dmNWFPOWIxcFNDanBFOEw1NThXblhzQnFGelBlbXFFdXhnSmMtSVBFU2wydGNGUzJFaF9LckVtT1gxQi1FenFMOTJMSVdTZW5qNDFBYmxvbUJNcE5sSGlFNmphUXZnTHlzYjJNODlNbDRRZzh4Z1VwRWk2bU…
$GLSI stock is down 19% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPQVlYRXJGcU52UkhTSUZWWlA4Wl9tLVJ2NEx1cU9hUm9VRnlRTGNGamNkdHh2ckZsUXlpQUxJcmFZcHVaV0hpUlhXdGY3MEZtZWpjRlVwUkdNVmRpTkxTQ2x0MHNWWWVCaXE1UmE4RzE2WVIza3ZDNXlCeDRXU1d0TXNSeUhDVUg3MTN4Ty…
Europe trial enrollment jump leaves Greenwich finalizing 10-K figures - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPR0dTSDJoOUcxNlpkXzdJRXhZb281c2prU2pwZWlEcmNYaWpVMVA0c1JfaTRBcHRNU0RzcHZjWUZLYTBZRVpqOTVJYW5lVW1LeHZYTy1ZdVJ3TzJCX1MyNmt3WE51dnJVQ3RqWGhzeWhEMEh1NW5XQzMzQVVQdkxLa3ZNWlV2YlhZYTNsbl…
Greenwich LifeSciences The Overlooked Need (NASDAQ:GLSI) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPYkJxWU51Yl9pOC1xSlptbTEzY0V0dWNETjdQWFl0bGJxSHdiNk9VM0s5b0kwbjRjdFBycHB6VEpqZXQxZGNHNDNFZWdQV3JmZ1ZKcFcyNmVYOTZXNFM3YS1ZVDJTMVE4YkJNaGN1ZmMxTlpIVGtKM0dNTzJVbi1yRjl0eHk2WVZjdWgzdG…
GLSI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5lTk13RzJhZkNuSndvMEZQTmEzelMtZHFRQ1NuSS0tb29UdVN3ZE1jS2VfdGRUOTlwRmZDbnhKc2ROWFdxMnNMV2thaXNXZ3BxLWw0Xzk4XzNKTWpYWE51UjdFSjNXU2ZFQ2pxWWxMRHFVM2ZxWDBjUGln?oc=5" target="_blank">GLS…
GLSI — Frequently Asked Questions
What is the current share price of Greenwich LifeSciences, Inc. (GLSI)?
As of 2026-09-07 16:24 PDT, Greenwich LifeSciences, Inc. (GLSI) trades at $15.95 on NasdaqCM. Its 52-week range is $7.85 to $33.56.
What is the market capitalisation of GLSI?
Greenwich LifeSciences, Inc. (GLSI) has a market capitalisation of $234.12M on NasdaqCM.
What is the P/E ratio of GLSI?
GLSI trades at a trailing price-to-earnings (P/E) ratio of -9.91. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 40.00.
Is GLSI a good stock to buy?
This page provides a data-driven analysis of Greenwich LifeSciences, Inc. (GLSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.